| Schedule of Asset Acquisition |
The following table summarizes the consideration for the XEPI Transaction for the year ended December 31, 2025. | | | | | | | | | | | | | | | | | | | | | | Consideration Type | | Counterparty | | Contractual Amount | | Allocated Purchase Price | | Upfront Payment - Asset Purchase Agreement | | Biofrontera | | $ | 3,000 | | | $ | 3,000 | | | Contingent Consideration - Achievement of Commercial Quantities | | Biofrontera | | 1,000 | | | 1,000 | | | Contingent Consideration - Achievement of Sales Based Milestones | | Biofrontera | | 6,000 | | | — | | | Contingent Consideration - Acceptance of Initial API Purchase | | Ferrer | | 1,200 | | | 1,200 | | | Xepi Transaction - Transaction Expenses | | Various | | 880 | | | 880 | | | | | | $ | 12,080 | | | $ | 6,080 | | | | | | | | | | Royalty Payments on Net Sales of Xepi | | Ferrer | | 7 | % | | — | % |
|
| Schedule of Intangible Assets and Goodwill |
Goodwill and other identifiable intangible assets consisted of the following: | | | | | | | | | | | | | March 31, 2026 | | December 31, 2025 | | Indefinite-lived intangible assets | | | | | Goodwill | $ | 24,681 | | | $ | 24,681 | | | Definite-lived intangible assets | | | | | Developed technology | 32,200 | | | 32,200 | | | Amended Sato license | 715 | | | 715 | | | Xepi | 6,080 | | | 6,080 | | | Xeglyze | 1,817 | | | 1,817 | | | Website development | 214 | | | 214 | | | Less: accumulated amortization | (2,586) | | | (1,556) | | | Total definite-lived intangible assets | 38,440 | | | 39,470 | | | Total goodwill and other identifiable intangible assets, net | $ | 63,121 | | | $ | 64,151 | |
The following table presents both definite and indefinite lived intangible assets as of March 31, 2026, comprised primarily of acquired product rights related to the LNHC, Inc. acquisition, as discussed in Note 4 — “Acquisition of LNHC, Inc.” and the asset acquisitions of XEPI and XEGLYZE in the fourth quarter of 2025, described above: | | | | | | | | | | | | | | | | | | | | | | | | Carrying Value | | | | Accumulated Amortization | | Net Book Value | Remaining Useful Life (Years) | | Definite-lived intangible assets | | | | | | | | | | Developed technology | $ | 32,200 | | | | | $ | (1,979) | | | $ | 30,221 | | 11.42 | | Amended Sato license | 715 | | | | | (141) | | | 574 | | 2.00 | | Xepi | 6,080 | | | | | (387) | | | 5,693 | | 5.84 | | Xeglyze | 1,817 | | | | | (54) | | | 1,763 | | 8.72 | | Website development | 214 | | | | | (25) | | | 189 | | 2.86 | | Total definite-lived intangible assets | $ | 41,026 | | | | | $ | (2,586) | | | $ | 38,440 | | | | Indefinite-lived intangible assets | | | | | | | | | | Goodwill | 24,681 | | | | | — | | | 24,681 | | | | Total goodwill and other identifiable intangible assets | $ | 65,707 | | | | | $ | (2,586) | | | $ | 63,121 | | |
|
| Schedule of Amortization Expense Expected to be Recognized |
The following table represents annual amortization of definite lived intangible assets for the next five fiscal years, and thereafter: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Developed Technology | | Amended Sato License | | Xepi | | Xeglyze | | Website Development | | Total | | 2026 (April 1 - December 31) | $ | 1,993 | | | $ | 214 | | | $ | 735 | | | $ | 152 | | | $ | 49 | | | $ | 3,143 | | | 2027 | 2,645 | | | 287 | | | 975 | | | 202 | | | 66 | | | 4,175 | | | 2028 | 2,653 | | | 73 | | | 980 | | | 203 | | | 66 | | | 3,975 | | | 2029 | 2,645 | | | — | | | 975 | | | 202 | | | 8 | | | 3,830 | | | 2030 | 2,645 | | | — | | | 975 | | | 202 | | | — | | | 3,822 | | | 2031 and thereafter | 17,640 | | | — | | | 1,053 | | | 802 | | | — | | | 19,495 | | | Total amortization | $ | 30,221 | | | $ | 574 | | | $ | 5,693 | | | $ | 1,763 | | | $ | 189 | | | $ | 38,440 | |
|